Introduction
The B cell lymphoproliferative disorders are a heterogeneous group of diseases with distinct clinical and laboratory features. Although chronic lymphocytic leukaemia (CLL) is the most common disease in Western countries, it is apparent that a number of patients, clinically mimicking CLL, correspond to B cell lymphomas (B-NHL) in leukaemic phase. A review of data in our laboratory over a 4-year period (1993) (1994) (1995) (1996) on patients presenting with lymphocytosis showed that 48% corresponded to CLL and 30% to B-NHL.
In a number of cases, particularly those evolving with leukaemia, there may be difficulties in establishing a precise diagnosis on the basis of morphology and immunophenotyping. Cytogenetic studies may be useful for the differential diagnosis of the B cell disorders as some of them are associated with distinct karyotypic abnormalities.
A number of translocations which have in common the breakpoint at 14q32, the locus for the immunoglobulin heavy chain (IgH) gene have been described in B cell malignancies. Follicular lymphoma carries the t(14;18)(q32;q21) in more than 80% of cases whilst 50-70% of mantle-cell lymphoma (MCL), [1] [2] [3] [4] [5] cases of splenic lymphoma with villous lymphocytes (SLVL) and lymphoplasmacytic lymphomas [6] [7] [8] [9] have the t(11;14)(q13;q32) involving the IgH gene locus and the BCL1/cyclin D1 gene. In addition, few reports have suggested that t(11;14) is present in rare cases of atypical CLL although some of these patients have clinical and/or laboratory features of MCL. 6, [10] [11] [12] [13] [14] [15] MCL in leukaemic phase may present diagnostic difficulties with other B-NHL and particularly atypical CLL. The translocation t (11;14) can be detected by standard cytogenetics, Southern blot, polymerase chain reaction (PCR) and fluorescence in situ hybridisation (FISH). 1, 3, 4, 5, 8, 11, [16] [17] [18] [19] In addition, m-RNA or protein expression of the cyclin D1 can be investigated by Northern blot and/or immunohistochemistry. 3, 4, 8, 14, [20] [21] [22] The karyotyping has limitations because of difficulties in obtaining metaphases particularly in chronic lymphoid malignancies. By contrast, FISH allows the study of interphase cells with the possibility of retrospective analysis in frozen cytocentrifuge made slides. Furthermore, FISH is more sensitive than Southern blot to detect BCL-1 rearrangement or the t (11;14) 3-5 and is more specific than cyclin D1 overexpression which may be found in other B cell disorders without t(11;14) such as hairy cell leukaemia, marginal zone lymphomas and immunocytomas. 20, 23 We have investigated systematically the diagnostic value of FISH to detect BCL-1 rearrangements in a selected group of B cell leukaemias which were difficult to classify by morphology and immunological markers. All these cases have also been investigated by FISH for trisomy 12 as this abnormality is frequent in atypical CLL.
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Materials and methods
Patients
Fifty-three patients with lymphocytosis (Ͼ10 × 10 9 /l) have been included. The suspected diagnosis was based on peripheral blood morphology and immunological markers. 25, 26 and histology, available in 33 cases in whom peripheral nodes were present and/or had splenectomy. The initial provisional diagnosis was as follows (Table 1) : CLL, which included mostly cases with more than 10% prolymphocytes (CLL/PL) and/or atypical CLL, the latter defined by the presence of more than 15% cleaved or lymphoplasmacytic cells; 24 B-PLL, when the majority of cells were prolymphocytes; MCL characterised by cells with speckled chromatin, slightly indented nucleus without prominent nucleolus and occasional cytoplasmic vacuolation; follicular lymphoma, characterised by small cells with no visible cytoplasm and smooth dense chromatin, and SLVL in which the cells were small or medium in size and had prominent cytoplasmic villi. Four cases remained unclassifiable. The two cases with B-PLL were selected on the Table 2 . b Details of these three cases are shown in Table 3 .
basis of the translocation t(11;14) previously detected by cytogenetics and were used as positive controls.
Immunophenotyping was performed by flow cytometry (FACScan) on mononuclear cells as previously described. 26 The markers evaluated were: surface immunoglobulin (Smlg), CD2, CD5, CD19, CD22, CD23, CD37, CD79b and FMC7. In selected cases CD10, CD11c, CD25 and CD103 were also tested. On the basis of the reactivity with CD5, CD23 and FMC7 and the intensity of Smlg and membrane CD22 and/or CD79b expression, all cases were given a score as previously described. 26, 27 Each marker has a value of one or zero according to whether it is typical or atypical for CLL. In most cases of CLL, the scores ranged from 3 to 5 and from 0 to 2 in the other B cell disorders.
FISH analysis of t(11;14) and trisomy 12
Peripheral blood isolated mononuclear cells fixed in Carnoy solution (methanol-acetic acid 3/1) and spread on slides were used in all but one case in whom spleen cells were analysed. Two cell lines, G519 and JVM2, which carry the translocation t(11;14)(q13;q32) were used as positive controls and cells from six normal individuals as negative controls. Three hundred interphase nuclei were scored in the normal samples.
Two cosmid probes, COS 6.7 and COS H1.5 (Dr E Schuuring, Leiden, The Netherlands) 28 were used to detect the presence of the t(11;14)(q13;q32). Both are localised on chromosome 11 band q13 encompassing a 750 kb region around the BCL1-MTC. COS 6.7, the most centromeric, is approximately 400 kb far from the CCND1 gene while COS H1.5 is 250 kb telomeric from CCND1, covering the area in which most of the breakpoints have been described in B cell disorders.
FISH was performed according to standard methods. The probes were labelled by nick-translation using biotin 16-dUTP (COS 6.7) (Boehringer, UK) and digoxigenin 11-dUTP (COS H1.5) (Boehringer). The slides were pretreated with RNAse (100 g/ml) and pepsin (50 mg/ml). Competition hybridisation by pre-annealing with 100-200-fold excess of Cot-1DNA was performed before hybridisation on slides previously denatured slide preparations, with a hybridisation mixture containing 40 ng of each probe.
Post-hybridisation washes were carried out in 1 × SSC and 0.1 × SSC at 45°C and 60°C, respectively. The biotinylated probe was detected by using fluorescein isothiocyanate conjugated (FITC) streptavidin (Vector Lab, UK), biotinylated goat anti-streptavidin (Vector Lab) and again FITC streptavidin antibodies. Incubations with mouse anti-digoxigenin followed by tetramethyl-rhodamin isothiocyanate conjugated (TRITC) rabbit anti-mouse (Sigma, Poole, UK) and TRITC goat anti-rabbit antibodies (Sigma) were used to detect the digoxigenin labelled probe. Nuclei were counterstained with DAPl/antifade solution (Vector Lab).
Trisomy 12 was investigated with a chromosome 12 centromeric specific probe (Dr Looijenga, Laboratory of Experimental Patho-Oncology, University Hospital, Rotterdam, The Netherlands) using a microwave-based FISH technique. Twenty-five nanograms of the probe, previously labelled by nick-translation with fluorescein-16-dUTP (Boehringer) were placed on the slides and these were simultaneously denaturated at 72°C on a hot plate for 2 min. Hybridisation took place in a microwave oven where the slides were irradiated for 5 min at 340 watts. Subsequently the slides were washed once in 0.2 × SSC0.2% Tween 20 for 1 min and mounted with DAPl antifade solution.
The slides were analysed on a Zeiss fluorescent microscope (Axiophot) and FISH images were captured and analysed using a cooled charge coupled device camera (Photometrics) with lPLab (Digital Scientific) software. A minimum of 200 nuclei per sample were analysed.
The normal hybridisation pattern for the BCL-1 rearrangement or t (11;14) was shown by the presence of two pairs of juxtaposed signals. The presence of two spots (one green and one red) separated by a distance greater than the diameter of a single hybridisation spot in combination with two colocalised signals was indicative of the translocation.
Results
FISH analysis
BCL-1 rearrangement was detected by FISH in 51 to 98% of interphase cells from 15 patients. These cases had been preliminary classified as: MCL (10), B-PLL (two), CLL/PL (one) and atypical CLL (two) (Table 1) (Figure 1) .
In normal samples, 94% of interphase nuclei showed two pairs of two colocalised signals and 6% showed a pair of split signals (standard deviation: 2.3). The resulting cut-off level was 10.7%. In the two cell lines, G519 and JVM2, a combination of one pair of colocalised spots and one pair of dissociated spots was found in 90% of the interphase nuclei and in all metaphases analysed.
Trisomy 12 was detected in 32 to 75% of interphase cells from eight patients (Table 1) . In normal controls, 99% of the cells had only two signals. The cut-off level was 2%. The cases included: CLL (five) of which one was typical, two atypical and two CLL/PL, one unclassifiable B-NHL and two cases provisionally classified as MCL (see below). One of the latter cases had both trisomy 12 and BCL-1 rearrangement. The pattern of FISH in this case was unusual as 32% of cells were trisomic for chromosome 12, 36% had four signals and the remaining 32% were disomic.
Clinical and laboratory features of patients with BCL-1 rearrangement
Mantle-cell lymphoma (10 cases):
In 10 cases FISH demonstrated BCL-1 rearrangement and confirmed the suspected Cells from all these cases had a mature B cell phenotype with CLL scores ranging from 1-2, except in one case in which the score was 0. CD5 was positive in all but one, whilst all cases were CD23 negative. A single patient had both t(11;14) and trisomy 12 and was originally classified on haematological and morphological grounds as MCL in blastic transformation. He presented with generalised organomegaly, high WBC and had an aggressive clinical course. The circulating lymphocytes were large in size, had indented nucleus with reticular chromatin and scanty cytoplasm and the immunophenotype was CD5 + , FMC7 + , strong CD22 and Smlg, CD79b
− and CD23 − (score 1). The other five cases in whom MCL was suspected but BCL-1 rearrangement or t(11;14) was not detected presented with organomegaly, lymphocytosis (5 to 48 × 10 9 /l) with CD5 + lymphocytes and low CLL scores (2 and 3).
Atypical CLL and CLL/PL with BCL-1 rearrangement (Table 2):
One out of the two atypical CLL patients (No. 1) presented with marked lymphocytosis, no organomegaly and had an aggressive clinical course. The other (No. 2) had moderate splenomegaly and the disease remained stable untreated for 13 years. Recently, this patient underwent splenectomy and the spleen histology was consistent with a diagnosis of MCL. Cells in both cases were CD5 + and CD23 − and had low CLL scores ( Table 2) .
The case originally classified as CLL/PL (No. 3) had lymphadenopathy, splenomegaly and lymphocytosis (Figure 2) . The cells were CD5, CD23 and FMC7 negative whilst expressed strong Smlg, weakly CD22 and were CD79b + . Spleen histology showed a diffuse infiltration by pleomorphic lymphoid cells with increased immunoblasts suggesting the diagnosis of CLL/PL or 'paraimmunoblastic' transformation of CLL. However on the basis of cyclin D1 expression and the t(11;14) could be finally classified as a 'blastoid' transformation of MCL
B-PLL:
These two cases had typical features of this disease such as marked splenomegaly, no lymphadenopathy and a raised WBC (80 and 170 × 10 9 /l) with circulating prolymphocytes with a prominent nucleolus. The cells expressed strong Smlg and were CD5
+ and FMC7 + and in one of the two, they were CD23 + (scores 1 and 2).
Clinical and laboratory features of B-NHL with trisomy 12 (Table 3)
Two 
Discussion
This study aimed at clarifying the diagnosis of B cell leukaemia in a group of patients difficult to classify by standard methodology by investigating the presence of BCL-1 rearrangement/t(11;14)(13;q32) and trisomy 12 by FISH analysis.
Our findings demonstrated that 10 out of 15 cases in whom a diagnosis of MCL was suspected by morphology and immunological markers, carried BCL-1 rearrangement. Therefore, FISH confirmed that these cases corresponded to MCL in leukaemic phase. Such incidence compares with other reported molecular genetic studies in MCL, diagnosed on lymph node histology, in which the frequency of the t(11;14) ranges from 50 up to 80%. [3] [4] [5] 17 Whether the remaining cases in whom a diagnosis of MCL was suspected by lymphocyte morphology and phenotype but in which we were unable to demonstrate BCL-1 rearrangement, corresponded to MCL with 
Figure 2
Circulating cells from a case classified as CLL/PL with the t(11;14) ( Table 2 , case 3). There is a mixture of small lymphocytes with clumped chromatin and some large prolymphocytoid cells.
Figure 3
Circulating cells from a case provisionally classified as MCL without t(11;14) but with trisomy 12 (Table 3 , case 5). The majority of cells are medium size and have an indented nucleus. absence of such abnormality, [3] [4] [5] and/or another B cell disease, eg atypical CLL, is uncertain. The clinical features, prominent organomegaly and mild lymphocytosis, and the morphological and immunophenotypic features of the cells were not those of CLL and/or other lymphoma, such as SLVL.
There have been few studies emphasising the value of FISH or fiber FISH to detect t (11;14) in cases of already histologically documented MCL, 1, 5, 18 as well as in atypical CLL. 11, 13, 19 Detection of t (11;14) or BCL-1 rearrangement by FISH seems to be more sensitive than cytogenetics that depends on obtaining metaphases and more accurate than Southern blot and PCR as these may fail to detect BCL-1 rearrangement in approximately 40% of cases due to alternative breakpoints outside the major translocation cluster (MTC) region not detectable by standard probes. [3] [4] [5] In addition to its sensitivity, FISH is more specific that detecting overexpression of cyclin D1, the gene that is activated by t (11;14) in MCL as this might occur through other mechanisms. Thus, cyclin D1 may be upregulated in other B cell diseases, such as hairy cell leukaemia, 14, 20 marginal zone lymphoma/SLVL, 8, 9 and even, in an occasional case of MCL 5 without evidence of the t (11;14) . It is likely that other hitherto unknown mechanisms than t (11;14) lead to the cyclin D1 overexpression in such cases.
The presence of the t (11;14) in CLL has been controversial. 2 This translocation has been reported with variable frequency (2-12%) in several series. 6, [10] [11] [12] 15, 29 In one single report up to 50% of CLL were found to have t(11;14), 13 but this study did not provide a detailed review of the morphology and/or immunological markers. Thus, it could not be ruled out that cases of MCL had been included. Most of the cases reported had atypical morphology including CLL/PL. 6, 11, 12, 15, 18, 29, 30 It should be noted that in the series of Cuneo, 11 28% of atypical CLL cases had t (11;14) and trisomy 12 and the majority (78%) of them had del13q14, abnormality, also common but not specific to CLL. This was interpreted as a support of a diagnosis of CLL. In the present study, three cases initially classified as atypical CLL or CLL/PL had rearrangement of BCL-1 by FISH and none had trisomy 12. One of these cases (No. 2) could be subsequently reclassified as MCL when spleen histology became available. In another case (No. 3), spleen and lymph node histology was equivocal as to whether they corre-sponded to a blastoid form of MCL or to a CLL/PL, also designated 'paraimmunoblastic' variant of CLL, 31 but cyclin D1 expression and the presence of BCL-1 rearrangement supported a diagnosis of blastoid form of MCL. Recently, the t(11;14) has been reported in two out of four cases of paraimmunoblastic transformation of CLL/lymphocytic lymphoma and it has been speculated that such cases may be intermediate between CLL in transformation and the blastoid form of MCL. 31 It is possible that our case (No. 3) finally classified as blastoid MCL with t(11;14) fit within this category. Indeed a case of atypical CLL with t(11;14) undergoing Richter's transformation has already been documented. 10 In the third case (No. 1), the final diagnosis was likely MCL but this required confirmation by histology. All these three cases had a phenotype atypical for CLL with scores of 2 or 1. Therefore, these findings indicate that although t (11;14) and/or BCL-1 rearrangement might be a rare feature of atypical CLL and/or CLL/PL, in those cases with both, atypical morphology and immunological markers, the possibility of a MCL needs to be considered. This is not always taken into account as CLL cases with t(11;14) and atypical morphology and immunophenotype have been documented. 18 This study has further confirmed our previous findings that trisomy 12 is mainly found in CLL/PL and atypical CLL. 24 Trisomy 12 was detected in two cases provisionally classified as MCL. One case also had BCL-1 rearrangement and it is possible that trisomy 12 was a secondary abnormality although clonal evolution was not proven. A recent study by Cuneo et al 32 has shown that up to 28% of MCL have partial or total trisomy 12 and this feature correlated with a shorter survival. The other case (No. 5) originally classified as MCL had a CLL score of 3, was CD5
+ , CD23 + and may had corresponded to an atypical CLL. The third case (No. 6) remained undefined by histology, but trisomy 12 supported the diagnosis of atypical CLL.
In summary, our findings demonstrate that FISH analysis investigating the presence of BCL-1 rearrangement and trisomy 12 is a useful diagnostic tool to clarify the nature of those leukaemic B cell disorders which raise diagnostic problems due to their atypical morphology, undefined immunophenotypic profile and histology. FISH has also the additional advantage of being more sensitive than Southern blot or PCR to detect the t (11;14) or BCL-1 rearrangement, as well as more specific that cyclin D1 overexpression by Northern blot or immunohistochemistry, since the latter may be found in a variety of B cell conditions other than MCL, with or without the t (11;14) .
